Clinical Trial: T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy

U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07300891) titled 'T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy' on Dec. 02.

Brief Summary: This is a Phase 2, single-arm, multicenter study, evaluating the anti-tumor efficacy of tumor-infiltrating lymphocyte (TIL) directed tislelizumab monotherapy (also known as BGB-A317) for refractory solid tumors in approximately 72 patients with centrally confirmed T cell inflamed GEP score >= 0.857, who have not been previously exposed to immunotherapy.

All patients must provide a tumor specimen for T cell inflamed GEP assessment. Archived tis...